Gilead Expands Hep C Portfolio With LG Life Sciences Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement gives Gilead rights to caspase inhibitors for fibrotic disease, including Phase II candidate LB84451 for chronic hepatitis C.